In this context, identification of early molecular steps in HCC development might be useful in characterizing efficient, clinically useful biomarkers in cirrhotic patients. The aim of the present ...

门静脉高压的非肝硬化肝内病因包括病因明确的疾病，如血吸虫病，以及病因不明确的疾病，如非肝硬化门静脉纤维化（non-cirrhotic portal fibrosis ...

A study published in The American Journal of Gastroenterology says that juice from dill and kosher pickles can halt the ...

FAITH trial: Feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma—Amulticenter, single arm, ...

THE effect of increased intra-abdominal pressure due to ascites upon portal and systemic hemodynamics has not been directly documented although the hemodynamics of ascitic cirrhotic patients have ...

Fibrolamellar hepatocellular carcinoma (FL-HCC) epidemiology, survival characteristics, and outcomes: Surveillance, epidemiology, and end results database (SEER) study.

Akero Therapeutics announced promising results from the 96-week Phase 2b HARMONY trial of efruxifermin (EFX) for treating pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH ...

Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience thrombocytopenia as a result of the combination of portal hypertension induced splenomegaly, decreased ...

Aim: This study investigated the relationship between portal hypertensive gastropathy (PHG) and splenomegaly, and the effect of laparoscopic splenectomy on PHG in cirrhotic patients with portal ...

Ten compensated cirrhotic patients with acute portal vein thrombosis were examined using abdominal ultrasound with color Doppler and contrast-enhanced CT scans. All patients received continuous ...

A combination of NfL, GFAP, tau, and UCHL1 was effective in diagnosing MHE in all cirrhotic patients (area under the receiver operating characteristic curve [hereinafter referred to as AUROC]: 0. ...

In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo ...